TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Brief Summary: Patients diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy were confirmed based on the European Federation of Neurological Societies/ Peripheral. Nerve Society Guideline. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Subsequently, patients receive NPB-01 1g/kg every 3weeks and evaluate the Inflammatory Neuropathy Cause and Treatment（INCAT） score and INCAT sensory sumscore（ISS） et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.


Options:
A: Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score (at Week 24)
B: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period (Up to 25 weeks)
C: Responder Rate (25 weeks)
D: proportion of patients with more than 1point improvement in the INCAT score relative to baseline at 28weeks. (28weeks); proportion of patients with more than 1point exacerbation in the INCAT score relative to 28weeks at 52weeks. (52weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Sanitation, Hygiene, Infant Nutrition Efficacy Project
Brief Summary: Globally, stunting affects 26% (165 million) of under-5-year children, underlies 15-17% of their mortality and leads to long-term cognitive deficits, fewer years and poorer performance in school, lower adult economic productivity, and a higher risk that their own children will also be stunted, perpetuating the problem into future generations. Stunting begins antenatally and peaks at 18-24 months of postnatal life, when mean length-for-age Z-score (LAZ) is about -2.0 among children living in Africa and Asia. Improving the diets of young children can reduce stunting, though, at best, only by about one-third. Frequent diarrheal illness has also been implicated. However, the effect of diarrhea on permanent stunting is relatively small, maybe because children grow at "catch-up" rates between illness episodes.

The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial is motivated by a 2-part premise:

* A major cause of child stunting and anemia is Environmental Enteric Dysfunction (EED). EED is a subclinical disorder of the small intestine, which is virtually ubiquitous among asymptomatic people living in low-income settings throughout the world. EED is characterized by increased permeability which facilitates microbial translocation into the systemic circulation and triggers chronic immune activation.
* The primary cause of EED is infant ingestion of fecal microbes due to living in conditions of poor quality and quantity of water, sanitation, and hygiene (WASH).


Options:
A: Change in hand washing behavior (The outcome is measured at baseline, and after 1 and 2 years of intervention. In addition, a measurement will occur 1 year after the intervention has finished to see whether improvements have been maintained.)
B: Infant length at 18 months (18 months of age. Protocol and Statistical Analysis Plan are available at https://osf.io/w93hy.); Infant hemoglobin at 18 months (18 months)
C: Diarrhea prevalence of children under five years old (Measured 24 months after the baseline survey (12 months after intervention complete))
D: Incidence of Diarrhea (2 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Sanitation, Hygiene, Infant Nutrition Efficacy Project
Brief Summary: Globally, stunting affects 26% (165 million) of under-5-year children, underlies 15-17% of their mortality and leads to long-term cognitive deficits, fewer years and poorer performance in school, lower adult economic productivity, and a higher risk that their own children will also be stunted, perpetuating the problem into future generations. Stunting begins antenatally and peaks at 18-24 months of postnatal life, when mean length-for-age Z-score (LAZ) is about -2.0 among children living in Africa and Asia. Improving the diets of young children can reduce stunting, though, at best, only by about one-third. Frequent diarrheal illness has also been implicated. However, the effect of diarrhea on permanent stunting is relatively small, maybe because children grow at "catch-up" rates between illness episodes.

The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial is motivated by a 2-part premise:

* A major cause of child stunting and anemia is Environmental Enteric Dysfunction (EED). EED is a subclinical disorder of the small intestine, which is virtually ubiquitous among asymptomatic people living in low-income settings throughout the world. EED is characterized by increased permeability which facilitates microbial translocation into the systemic circulation and triggers chronic immune activation.
* The primary cause of EED is infant ingestion of fecal microbes due to living in conditions of poor quality and quantity of water, sanitation, and hygiene (WASH).


Options:
A: Diarrhea prevalence of children under five years old (Measured 24 months after the baseline survey (12 months after intervention complete))
B: Incidence of Diarrhea (2 weeks)
C: Infant length at 18 months (18 months of age. Protocol and Statistical Analysis Plan are available at https://osf.io/w93hy.); Infant hemoglobin at 18 months (18 months)
D: Length-for-Age Z-scores (Measured 24 months after intervention); Diarrhea Prevalence Diarrhea Prevalence Diarrhea Prevalence Diarrhea Prevalence (Measured 12- and 24-months after intervention)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Sanitation, Hygiene, Infant Nutrition Efficacy Project
Brief Summary: Globally, stunting affects 26% (165 million) of under-5-year children, underlies 15-17% of their mortality and leads to long-term cognitive deficits, fewer years and poorer performance in school, lower adult economic productivity, and a higher risk that their own children will also be stunted, perpetuating the problem into future generations. Stunting begins antenatally and peaks at 18-24 months of postnatal life, when mean length-for-age Z-score (LAZ) is about -2.0 among children living in Africa and Asia. Improving the diets of young children can reduce stunting, though, at best, only by about one-third. Frequent diarrheal illness has also been implicated. However, the effect of diarrhea on permanent stunting is relatively small, maybe because children grow at "catch-up" rates between illness episodes.

The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial is motivated by a 2-part premise:

* A major cause of child stunting and anemia is Environmental Enteric Dysfunction (EED). EED is a subclinical disorder of the small intestine, which is virtually ubiquitous among asymptomatic people living in low-income settings throughout the world. EED is characterized by increased permeability which facilitates microbial translocation into the systemic circulation and triggers chronic immune activation.
* The primary cause of EED is infant ingestion of fecal microbes due to living in conditions of poor quality and quantity of water, sanitation, and hygiene (WASH).


Options:
A: Infant length at 18 months (18 months of age. Protocol and Statistical Analysis Plan are available at https://osf.io/w93hy.); Infant hemoglobin at 18 months (18 months)
B: Maternal primary outcome is child length at birth (0 - 48 hr after birth); Child primary outcome is child length-for-age Z-score (LAZ, based on WHO 2006 growth standards) at 18 months of age (18 months after birth)
C: Incidence of severe acute malnutrition (15 months)
D: Length-for-Age Z-scores (Measured 24 months after intervention); Diarrhea Prevalence Diarrhea Prevalence Diarrhea Prevalence Diarrhea Prevalence (Measured 12- and 24-months after intervention)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Sanitation, Hygiene, Infant Nutrition Efficacy Project
Brief Summary: Globally, stunting affects 26% (165 million) of under-5-year children, underlies 15-17% of their mortality and leads to long-term cognitive deficits, fewer years and poorer performance in school, lower adult economic productivity, and a higher risk that their own children will also be stunted, perpetuating the problem into future generations. Stunting begins antenatally and peaks at 18-24 months of postnatal life, when mean length-for-age Z-score (LAZ) is about -2.0 among children living in Africa and Asia. Improving the diets of young children can reduce stunting, though, at best, only by about one-third. Frequent diarrheal illness has also been implicated. However, the effect of diarrhea on permanent stunting is relatively small, maybe because children grow at "catch-up" rates between illness episodes.

The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial is motivated by a 2-part premise:

* A major cause of child stunting and anemia is Environmental Enteric Dysfunction (EED). EED is a subclinical disorder of the small intestine, which is virtually ubiquitous among asymptomatic people living in low-income settings throughout the world. EED is characterized by increased permeability which facilitates microbial translocation into the systemic circulation and triggers chronic immune activation.
* The primary cause of EED is infant ingestion of fecal microbes due to living in conditions of poor quality and quantity of water, sanitation, and hygiene (WASH).


Options:
A: Early Child Development (24 months of child age); Child Growth (24 months of child age)
B: Infant length at 18 months (18 months of age. Protocol and Statistical Analysis Plan are available at https://osf.io/w93hy.); Infant hemoglobin at 18 months (18 months)
C: HIV infection detected by 4 months among children with no evidence of HIV infection at birth. (24 months of age); Magnitude of the reduction in mother-to-child HIV transmission and the magnitude of the increase in non-HIV-related under-2-year mortality, attributable to cessation of breastfeeding at 4 months.
D: Frequency of exclusive and total breastfeeding (First year)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Reduction of Early mortALITY in HIV-infected African Adults and Children Starting Antiretroviral Therapy: a Randomised Controlled Trial
Brief Summary: A randomised controlled trial to investigate three methods to reduce early mortality in adults, adolescents and children aged 5 years or older starting antiretroviral therapy (ART) with severe immuno-deficiency. The three methods are:

(i) increasing the potency of ART with a 12 week induction period using 4 antiretroviral drugs from 3 classes

(ii) augmented prophylaxis against opportunistic/bacterial infections and helminths for 12 weeks

(iii) macronutrient intervention using ready-to-use supplementary food for 12 weeks.


Options:
A: Number of Participants With Nutritional Recovery (12 weeks or upon completion of recovery); Number of Patients With Absence of Bilateral Pedal Pitting Edema (12 weeks or recovery)
B: weight-for-height in children 6 to 60 mo of age (8 months)
C: Total long chain PUFA in erythrocyte membranes at 3 months (3 months)
D: All-cause mortality over the first 24 weeks after starting ART (Week 24)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Musculoskeletal Consequences of Pediatric Overweight - Efficiency of Different Interventions on Health, Motor and Psychosocial Development in Overweight and Obese Children
Brief Summary: The purpose was to investigate the consequences of pediatric overweight on the musculoskeletal system, postural control and proprioception, and to analyze prospectively the influence of ball games and nutrition counseling.


Options:
A: NeuroCognitive Assessment (Change from baseline, 36 - 40 weeks); Structural Magnetic Resonance Imaging (Change from baseline, 36 - 40 weeks); Functional Magnetic Resonance Imaging (Change from baseline, 36 - 40 weeks); Academic Achievement (Change from baseline, 36 - 40 weeks); Eye Tracking (Change from baseline, 36 - 40 weeks); Task Performance (Change from baseline, 36 - 40 weeks)
B: Change in error points in one legged-standing test (at baseline and 6 months later after intervention)
C: Change in BMI z-score (Baseline (0 months) and 9 months)
D: For adults: body weight loss maintenance (6 Month)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: THE IMPACT OF THE ENHANCED HOMESTEAD FOOD PRODUCTION PROGRAM ON CHILD HEALTH
Brief Summary: Helen Keller International (HKI) has been implementing homestead food production (HFP) programs in Asia for the past 20 years and has recently begun implementing HFP programs in Africa as well. In general, these programs target women and are designed to improve maternal and child health and nutrition outcomes through three primary pathways: 1. Increasing the availability of micronutrient-rich foods through increased household production of these foods; 2. Raising income through the sale of surplus production; and 3. Increasing knowledge and adoption of optimal nutrition practices, including the consumption of micronutrient-rich foods. Evaluations of HFP programs have consistently demonstrated significant increases in household production and consumption of micronutrient-rich foods. This increased consumption, along with improvements in health and nutrition related knowledge, and increased income, could all contribute to improvements in maternal and child health and nutrition outcomes. However, to date there has been limited understanding as to how these types of programs can be optimized to maximize impacts on these outcomes.

In order to better understand the potential of these types of programs to improve maternal and child health and nutrition outcomes and how this impact may be achieved IFPRI has been collaborating with HKI to evaluate one of their E-HFP programs in Burkina Faso. The evaluation considers impact of the program through the three pathways above, and assesses anthropometric and clinical measures of nutrition, as well as looking at how the programs might be improved.


Options:
A: Growth (Measurements will be made for children between the ages of 3 and 12 months of age at baseline and then 2 years later, at endline, when the children are between the ages of 23 and 40 months); Hemoglobin (Measurements will be made for children between the ages of 3 and 12 months of age at baseline and then 2 years later, at endline, when the children are between the ages of 23 and 40 months)
B: Incidence of Diarrhea (2 weeks)
C: Food security as measured by the value of food consumption through a household questionnaire (6 months); Dietary diversity as measured by dietary diversity index and food consumption score through a household questionnaire (6 months)
D: Number of Participants With HIV Viral Load < 40 Copies/ML at 1 Year (1 year); Change From Baseline in CD4 Count at 1 Year (1 year)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: THE IMPACT OF THE ENHANCED HOMESTEAD FOOD PRODUCTION PROGRAM ON CHILD HEALTH
Brief Summary: Helen Keller International (HKI) has been implementing homestead food production (HFP) programs in Asia for the past 20 years and has recently begun implementing HFP programs in Africa as well. In general, these programs target women and are designed to improve maternal and child health and nutrition outcomes through three primary pathways: 1. Increasing the availability of micronutrient-rich foods through increased household production of these foods; 2. Raising income through the sale of surplus production; and 3. Increasing knowledge and adoption of optimal nutrition practices, including the consumption of micronutrient-rich foods. Evaluations of HFP programs have consistently demonstrated significant increases in household production and consumption of micronutrient-rich foods. This increased consumption, along with improvements in health and nutrition related knowledge, and increased income, could all contribute to improvements in maternal and child health and nutrition outcomes. However, to date there has been limited understanding as to how these types of programs can be optimized to maximize impacts on these outcomes.

In order to better understand the potential of these types of programs to improve maternal and child health and nutrition outcomes and how this impact may be achieved IFPRI has been collaborating with HKI to evaluate one of their E-HFP programs in Burkina Faso. The evaluation considers impact of the program through the three pathways above, and assesses anthropometric and clinical measures of nutrition, as well as looking at how the programs might be improved.


Options:
A: Number of Participants With HIV Viral Load < 40 Copies/ML at 1 Year (1 year); Change From Baseline in CD4 Count at 1 Year (1 year)
B: Targeted fruit and vegetable (TFV) intake (Intake in prior 24 hours; assessed in two follow-up rounds (4-6 mo and 9-11 mo post-implementation) with 10% replicate subsample in each round; data pooled across two follow-up rounds and replicate samples for primary analysis)
C: Recovery rate in the outpatient therapeutic program (At 6 week)
D: Growth (Measurements will be made for children between the ages of 3 and 12 months of age at baseline and then 2 years later, at endline, when the children are between the ages of 23 and 40 months); Hemoglobin (Measurements will be made for children between the ages of 3 and 12 months of age at baseline and then 2 years later, at endline, when the children are between the ages of 23 and 40 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: THE IMPACT OF THE ENHANCED HOMESTEAD FOOD PRODUCTION PROGRAM ON CHILD HEALTH
Brief Summary: Helen Keller International (HKI) has been implementing homestead food production (HFP) programs in Asia for the past 20 years and has recently begun implementing HFP programs in Africa as well. In general, these programs target women and are designed to improve maternal and child health and nutrition outcomes through three primary pathways: 1. Increasing the availability of micronutrient-rich foods through increased household production of these foods; 2. Raising income through the sale of surplus production; and 3. Increasing knowledge and adoption of optimal nutrition practices, including the consumption of micronutrient-rich foods. Evaluations of HFP programs have consistently demonstrated significant increases in household production and consumption of micronutrient-rich foods. This increased consumption, along with improvements in health and nutrition related knowledge, and increased income, could all contribute to improvements in maternal and child health and nutrition outcomes. However, to date there has been limited understanding as to how these types of programs can be optimized to maximize impacts on these outcomes.

In order to better understand the potential of these types of programs to improve maternal and child health and nutrition outcomes and how this impact may be achieved IFPRI has been collaborating with HKI to evaluate one of their E-HFP programs in Burkina Faso. The evaluation considers impact of the program through the three pathways above, and assesses anthropometric and clinical measures of nutrition, as well as looking at how the programs might be improved.


Options:
A: Growth (Measurements will be made for children between the ages of 3 and 12 months of age at baseline and then 2 years later, at endline, when the children are between the ages of 23 and 40 months); Hemoglobin (Measurements will be made for children between the ages of 3 and 12 months of age at baseline and then 2 years later, at endline, when the children are between the ages of 23 and 40 months)
B: Infant length at 18 months (18 months of age. Protocol and Statistical Analysis Plan are available at https://osf.io/w93hy.); Infant hemoglobin at 18 months (18 months)
C: Percent of infants sleeping 5 consecutive hours at night at 2 months of age (2.5 years)
D: Exclusive breastfeeding (EBF) among children 0-6 months of age (4 years after baseline); Child anthropometry (height, weight) among children 24-48 months of age (4 years after baseline); Complementary feeding among children 6-23.9 months of age (4 years after baseline); Anemia among children 6-23.9 months (4 years after baseline)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies
Brief Summary: Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate efficacy and safety of a 12-months treatment with deferiprone (DFP) at dose of 75-100 mg/kg/day versus deferasirox (DFX) at dose of 20-40 mg/kg/day in paediatric patients (1 month \< 18 years old) affected by hereditary haemoglobinopathies and requiring frequent transfusions and chelation.


Options:
A: Change From Baseline in Liver Iron Concentration (LIC) (Change from baseline to Week 52)
B: Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event (up to 5 years)
C: Clinical efficacy (Iron balance and liver iron concentration) (At baseline and at 12 months)
D: Percentage of Successfully Chelated Patients (at baseline and after 12 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Effects of Simple Sodium Alignment on Short-, Medium- and Long-term Clinical and Laboratory Outcome Measures
Brief Summary: A difference between dialysate and serum sodium concentration leads to diffusive sodium transfer across the dialyzer membrane. The consequences of diffusive sodium flux into the patient can be chronic sodium overload leading to overhydration, hypertension, cardiovascular disease, and other problems. Diffusive sodium flux out of the patient can lead to intradialytic blood pressure instability. A simple strategy for alignment of dialysate and serum sodium concentrations was implemented starting in April/May 2010 in order to minimize the problems particularly associated with chronic sodium overload.


Options:
A: Intra-Dialytic Hypotension (60 days)
B: a composite of mortality with the change over 12 months in left ventricular mass (12 months); a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite. (12 months)
C: Interdialytic weight gain (Each dialysis treatment (3x per week) - 2 years of treatment data); Pre-dialysis Blood Pressure (Each dialysis treatment (3x per week)- 2 years of treatment data)
D: composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, (12 months); a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite (12 months)

Answer: C